CoChat
Sign Up
Cited by 307Acute Ischemic Stroke ManagementAtrial Fibrillation Management and OutcomesCardiovascular and Diving-Related Complications

The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.

Efficacy and Safety of Anticoagulant Treatment in Acute Cardioembolic Stroke: A Meta-Analysis of Randomized Controlled Trials

Paciaroni, Maurizio, Agnelli, Giancarlo, Micheli, Sara, Caso, Valeria·2007·Stroke
DOI 10.1161/01.str.0000254600.92975.1f
Open this paper in CoChat — free account

Abstract

BACKGROUND AND PURPOSE: The role of anticoagulant treatment for acute cardioembolic stroke is uncertain. We performed an updated meta-analysis of all randomized trials to obtain the best estimates of the efficacy and safety of anticoagulants for the initial treatment of acute cardioembolic stroke. METHODS: Using electronic and manual searches of the literature, we identified randomized trials comparing anticoagulants (unfractionated heparin or low-molecular-weight heparin or heparinoids), started within 48 hours, with other treatments (aspirin or placebo) in patients with acute ischemic cardioembolic stroke. Two reviewers independently selected studies and extracted data on study design, quality, and clinical outcomes, including death or disability, all strokes, recurrent ischemic stroke, and cerebral symptomatic bleeding. Odds ratios for individual outcomes were calculated for each trial and data from all the trials were pooled using the Mantel-Haenszel method. RESULTS: Seven trials, involving 4624 patients with acute cardioembolic stroke, met the criteria for inclusion. Compared with other treatments, anticoagulants were associated with a nonsignificant reduction in recurrent ischemic stroke within 7 to 14 days (3.0% versus 4.9%, odds ratio 0.68, 95% CI: 0.44 to 1.06, P=0.09, number needed to treat=53), a significant increase in symptomatic intracranial bleeding (2.5% versus 0.7%, odds ratio 2.89; 95% CI: 1.19 to 7.01, P=0.02, number needed to harm=55), and a similar rate of death or disability at final follow up (73.5% versus 73.8%, odds ratio 1.01; 95% CI: 0.82 to 1.24, P=0.9). CONCLUSIONS: Our findings indicate that in patients with acute cardioembolic stroke, early anticoagulation is associated with a nonsignificant reduction in recurrence of ischemic stroke, no substantial reduction in death and disability, and an increased intracranial bleeding.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/01.str.0000254600.92975.1f

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Research works printed but not linked: 11

  1. 10.1161/str.22.3.2003301 · DOI
  2. 10.1161/str.14.5.6658950 · DOI
  3. Cazzato G, Zorzon M, Mase G, Antonutti L, Iona LG. Il mesoglicano nelle ischemie cerebrali acute a focolaio. Rev Neurol. 1989; 59: 121–126.
  4. Kwiecinski H, Pniewski J, Kaminska A, Szyluk B. A randomized trial of Fraxiparine in acute ischemic stroke [Abstract]. Cerebrovasc Dis. 1995; 5: 234.
  5. 10.1161/str.32.1.22 · DOI
  6. 10.1161/str.21.9.2396265 · DOI
  7. 10.1161/str.32.10.2333 · DOI
  8. 10.1161/str.14.5.6362091 · DOI
  9. 10.1161/str.33.3.856 · DOI
  10. 10.1161/str.30.7.1326 · DOI
  11. 10.1161/str.31.7.1770 · DOI

Cited by

Sorted by citations

Items 201–300 of 306

Related

See all

Metadata

Authors
Paciaroni, M., Agnelli, G., Micheli, S., & Caso, V.
Affiliations
University of Perugia (IT)
ORCID
Venue
Stroke
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2007-02
Volume
38
Issue
2
Pages
423-430
ISSN
  • 0039-2499 (ISSN-L)
  • 1524-4628
DOI
10.1161/01.str.0000254600.92975.1f
OpenAlex
W2138775201
Cited by
307
References
48
Citations by year
2026: 8 · 2025: 4 · 2024: 7 · 2023: 17 · 2022: 23 · 2021: 26 · 2020: 17 · 2019: 19 · 2018: 12 · 2017: 16 · 2016: 20 · 2015: 15 · 2014: 22 · 2013: 19 · 2012: 14
FWCI
12.84
Type
journal article
Language
en
Open access
closed
Locations
  • Stroke (publishedVersion)
  • PubMed (publishedVersion)
  • Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cardiovascular and Diving-Related Complications
Keywords
cardioembolic stroke, anticoagulation, heparin, low molecular weight heparin, heparinoids, aspirin, recurrent ischemic stroke, intracranial hemorrhage, stroke mortality and disability
MeSH terms
Anticoagulants, Embolism, Humans, Randomized Controlled Trials as Topic, Myocardial Ischemia, Stroke

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review